Research progress of therapeutic antibodies against COVID-19
Chinese Journal of New Drugs
; 31(21):2073-2081, 2022.
Article
in Chinese
| EMBASE | ID: covidwho-2111995
ABSTRACT
Antibody-based biological products have gradually become a new strategy for the treatment of infectious diseases. In the past few years, especially after the outbreak of the COVID-19 in 2019, researches on therapeutic SARS-CoV-2 antibodies have greatly developed. Researchers around the world have developed a series of antibody treatment programs with extremely high efficiency to fight against COVID-19. From the early days of the pandemic, therapeutic antibodies were only used for emergency treatment of clinically severe patients, now they can be used for both pre-exposure prophylaxis and post-infection treatment. We summarize the research progress of therapeutic antibodies for SARS-CoV-2, including convalescent plasma, animal antiserum, marketed mAbs, non-targeted therapeutic mAbs, and bispecific antibodies, etc. The limitations and future application prospects of the SARS-CoV-2 therapeutic mAbs are also discussed. Copyright © 2022, Chinese Journal of New Drugs Co. Ltd. All right reserved.
Search on Google
Collection:
Databases of international organizations
Database:
EMBASE
Language:
Chinese
Journal:
Chinese Journal of New Drugs
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS